Principal Financial Group Inc Cellectis S.A. Transaction History

Principal Financial Group Inc

$162 Billion
Q1 2024

A detailed history of Principal Financial Group Inc transactions in Cellectis S.A. stock. As of the latest transaction made, Principal Financial Group Inc holds 424,533 shares of CLLS stock, worth $806,612. This represents 0.0% of its overall portfolio holdings.

Number of Shares

424,533

Previous 399,627 6.23%

Holding current value

$806,612

Previous $1.23 Million 8.54%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$2.41 - $3.09 $60,023 - $76,959	24,906 Added 6.23%	424,533 $1.13 Million
Q4 2023 Feb 07, 2024	SELL	$0.97 - $3.55 $249,263 - $912,254	-256,973 Reduced 39.14%	399,627 $1.23 Million
Q3 2023 Nov 02, 2023	SELL	$1.58 - $2.86 $16,496 - $29,861	-10,441 Reduced 1.57%	656,600 $1.04 Million
Q2 2023 Aug 07, 2023	SELL	$1.72 - $2.12 $1.2 Million - $1.47 Million	-694,819 Reduced 51.02%	667,041 $1.31 Million
Q1 2023 May 09, 2023	BUY	$1.83 - $3.84 $50,892 - $106,790	27,810 Added 2.08%	1,361,860 $2.63 Million

Q4 2022 Feb 09, 2023	SELL	$1.85 - $2.53 $17,421 - $23,825	-9,417 Reduced 0.7%	1,334,050 $2.8 Million
Q3 2022 Nov 09, 2022	SELL	$2.42 - $4.08 $11,724 - $19,767	-4,845 Reduced 0.36%	1,343,467 $3.08 Million
Q2 2022 Aug 10, 2022	BUY	$2.39 - $4.93 $319,272 - $658,583	133,587 Added 11.0%	1,348,312 $3.82 Million
Q1 2022 May 09, 2022	SELL	$3.45 - $8.77 $37,356 - $94,961	-10,828 Reduced 0.88%	1,214,725 $5.52 Million
Q4 2021 Feb 09, 2022	SELL	$8.01 - $12.84 $126,309 - $202,473	-15,769 Reduced 1.27%	1,225,553 $9.95 Million
Q3 2021 Nov 09, 2021	SELL	$11.94 - $16.09 $251,528 - $338,951	-21,066 Reduced 1.67%	1,241,322 $15.7 Million
Q2 2021 Aug 10, 2021	BUY	$14.36 - $20.93 $18.1 Million - $26.4 Million	1,262,388 New	1,262,388 $19.5 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

9.83M

Call Options Held

Put Options Held

30.9K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86.5M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Cellectis S.A. Transaction History